Phreesia, Inc.
No SEC Form 4 filings for $PHR in the last 30 days.
See all $PHR insider activity →Citizens maintained a Market Perform rating on Phreesia (PHR) after mixed industry feedback. The stock trades at $11.28, with potential upside according to InvestingPro. Q2 2027 revenue rose 10% YoY to $129.5M, beating estimates, but EPS missed. Analysts have varied outlooks on growth and profitability.
Phreesia (PHR) reported Q2 revenue of $129.5M (up 10%) and adjusted EBITDA of $32.9M (up 25%). Net income was $1.9M, marking 5 straight profitable quarters. Management reaffirmed FY guidance. Analysts are divided: some raised targets citing margin improvements, while others downgraded due to slower growth and healthcare IT pressures.
Phreesia (PHR) reported Q2 2027 revenue of $129.5M and adjusted EBITDA of $32.9M, marking five straight quarters of positive net income. Revenue grew 10% YoY, with client count and revenue per client also increasing. The company reduced debt by $23M and credited AI for operational efficiencies. However, management warned of increased unpredictability in network solutions revenue due to financial strain on healthcare providers. Phreesia reaffirmed its full-year revenue and EBITDA guidance.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PHR (Phreesia, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PHR coverage spans earnings, market movers and corporate actions.
Mixed feedback and downgrade may weigh on the stock.
Improved margins and cash flow support upside, but slower growth and reduced visibility increase risk.
Strong profitability and debt reduction may support upside, but reduced visibility in network solutions and strained client base pose downside risks.
Strong top-line growth and raised guidance suggest upside potential for the stock.
The downgrade and earnings concerns triggered a sharp intraday sell-off.
AlphAI scores every news story that mentions PHR with an AI model for sentiment and relevance, and aggregates insider trades from Phreesia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Citizens maintained a Market Perform rating on Phreesia (PHR) after mixed industry feedback. The stock trades at $11.28, with potential upside according to InvestingPro. Q2 2027 revenue rose 10% YoY to $129.5M, beating estimates, but EPS missed. Analysts have varied outlooks on growth and profitability.
1 min readPhreesia (PHR) reported Q2 revenue of $129.5M (up 10%) and adjusted EBITDA of $32.9M (up 25%). Net income was $1.9M, marking 5 straight profitable quarters. Management reaffirmed FY guidance. Analysts are divided: some raised targets citing margin improvements, while others downgraded due to slower growth and healthcare IT pressures.
3 min readPhreesia (PHR) reported Q2 2027 revenue of $129.5M and adjusted EBITDA of $32.9M, marking five straight quarters of positive net income. Revenue grew 10% YoY, with client count and revenue per client also increasing. The company reduced debt by $23M and credited AI for operational efficiencies. However, management warned of increased unpredictability in network solutions revenue due to financial strain on healthcare providers. Phreesia reaffirmed its full-year revenue and EBITDA guidance.
3 min readPhreesia (PHR) reported Q2 2027 revenue of $129.5M, up 10% YoY, with adjusted EBITDA of $32.9M and net income of $1.9M. AHSCs grew 6% to 4,744. Full-year guidance: revenue $510M-$520M, adjusted EBITDA $125M-$135M. Management noted variability in revenue forecasting and economic pressures on healthcare providers.
2 min readPhreesia (PHR) stock fell 7% Tuesday due to bearish sentiment after Q2 earnings and a downgrade by Raymond James analyst John Ransom. Ransom cited declining organic revenue growth and AI spending pressures. Despite a 10% revenue increase, concerns remain about future performance and market constraints.
2 min readDA Davidson reduced its price target for Phreesia Inc. (NYSE:PHR) to $13.00 from $14.00, citing adjusted revenue assumptions and growth timelines. The firm maintained a Buy rating, noting mixed Q2 fiscal 2027 results with revenue of $129.5M and adjusted EBITDA of $32.9M. Phreesia's stock trades at $10.92, below analyst consensus targets ranging from $10 to $20.
2 min readPhreesia (PHR) shares fell 6.33% after reporting Q2 2027 revenue of $129.5M, up 10% YoY, and GAAP net income of $1.9M. While revenue beat estimates, earnings per share missed expectations. The company maintained full-year guidance and highlighted recent product launches.
2 min readPhreesia, Inc. (PHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phreesia Announces Second Quarter Fiscal 2027 Results ALL-REMOTE COMPANY/WILMINGTON, Del., September 2, 2026 – Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026. “Phreesia deli
2 min readPhreesia, Inc. (PHR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. phr-20260624 false 0001412408 0001412408 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities
3 min readEdward L. Cahill, a director at Phreesia, Inc. (NYSE: PHR), opted to receive 1,085 shares of common stock valued at $9.21 per share as deferred stock units, instead of a cash retainer. This decision was made under the company's Non-Employee Director Deferred Compensation Program. Following this grant, Cahill directly holds 65,613 shares of Phreesia common stock, with the underlying shares to be delivered upon his departure from the board or five years from the grant date.
2 min read
